GlassScriptPhysician profile
Benjamin J Wagner
NPI 1447591565
$12,861.62
in general payments reported to CMS, 2019-2025
41 companies · $3,600 in 2025
The $3,600 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,025 · 2022: $1,851 · 2023: $2,228 · 2024: $2,157 · 2025: $3,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,985.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,556.37 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,339.99 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,222.18 | 2021-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $1,105.15 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $1,060.04 | 2021-2025 | Rexulti, Vyepti, Brintellix |
| Neurocrine Biosciences, INC. | $1,059.13 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $697.82 | 2021-2025 | Spravato |
| Alkermes, INC. | $697.28 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $549.70 | 2021-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $489.04 | 2022-2025 | Auvelity, Sunosi |
| Sunovion Pharmaceuticals INC. | $456.58 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $420.92 | 2021-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $332.98 | 2022-2024 | Quviviq |
| Bausch Health US, LLC | $245.16 | 2021-2025 | Wellbutrin, Aplenzin |
| Avanir Pharmaceuticals, INC. | $230.74 | 2021-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $197.39 | 2025 | Cobenfy |
| Arbor Pharmaceuticals, INC. | $150.88 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $131.74 | 2021-2022 | |
| Biogen, INC. | $84.43 | 2024 | |
| Indivior INC. | $76.64 | 2021-2025 | Sublocade |
| Eisai INC. | $74.26 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $69.14 | 2022-2025 | Qelbree |
| Nevro Corp. | $59.33 | 2022 | |
| Corium, LLC | $55.38 | 2022-2025 | Azstarys |
| Luye Pharma (USA) LTD. | $54.53 | 2025 | Erzofri Extended-Release |
| Noven Therapeutics, LLC | $50.91 | 2024 | Xelstrym, Secuado |
| Livanova USA, INC. | $48.50 | 2023-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Alfasigma USA, INC. | $39.26 | 2021-2022 | |
| Orexo US, INC. | $36.28 | 2021-2022 | |
| Harmony Biosciences LLC | $34.64 | 2023 | Wakix |
| Biohaven Pharmaceuticals, INC. | $33.00 | 2021 | |
| Ge Healthcare | $29.15 | 2021-2023 | |
| Averitas Pharma INC. | $23.00 | 2025 | Qutenza |
| Tanabe Pharma America, INC. | $22.48 | 2025 | Radicava |
| Merck Sharp & Dohme LLC | $21.28 | 2022 | |
| Merz Pharmaceuticals, LLC | $20.87 | 2025 | Xeomin, Inbrija |
| Astrazeneca Pharmaceuticals LP | $20.78 | 2025 | Wainua |
| Collegium Pharmaceutical, INC. | $19.29 | 2025 | Jornay Pm |
| Janssen Biotech, INC. | $17.72 | 2025 | |
| Avion Pharmaceuticals | $15.55 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.